News &Â Press.
Learn the Latest Aziyo Updates
Aziyo Biologics to Participate in Upcoming Investor Conferences
SILVER SPRING, Md., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today...
Aziyo Biologics Reports Strong Third Quarter 2022 Revenue; Positive meeting with FDA provides clarity for CanGaroo® RM clearance
SILVER SPRING, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today...
Aziyo Biologics to Report Third Quarter 2022 Financial Results on November 14, 2022
SILVER SPRING, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced that it will release third quarter 2022 financial results after...
Aziyo Biologics Appoints Seasoned Healthcare Executive, David Colpman, to Board of Directors; Industry veteran brings more than 25 years of healthcare business development and transaction experience
SILVER SPRING, Md., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a regenerative medicine company with a portfolio of commercial therapies, today announced the appointment of David Colpman to its Board of Directors and...
Aziyo Biologics Strengthens Leadership Team and Organizes for Growth in Key Markets; Senior team enhanced to advance Aziyo’s commercial and financial objectives
SILVER SPRING, Md., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biological device company with a portfolio of commercial products across four distinct businesses, today announced key promotions and new hires that...